Navigation Links
Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs
Date:8/22/2014

WASHINGTON, Aug. 22, 2014 /PRNewswire-USNewswire/ -- Today, the Obama Administration issued new regulations under Obamacare that modify the religious "accommodation" but still require religious organizations to facilitate insurance coverage for drugs that have an abortifacient effect, including Plan B (the "morning after pill") and Ella (the "week after pill"). The Obama Administration also announced that it is investigating expanding the "accommodation" to religious, closely held, for-profit corporations.

The regulations issued today keep the same "accommodation" in place but provide an alternative means of accepting the "accommodation." Instead of submitting the previously required form, religious organizations may now elect instead to notify the government in writing of their objection to providing the abortifacient coverage using words of the organization's own choice.

"Eliminating the requirement of using the government's form does not eliminate moral liability for facilitating coverage of these abortifacient drugs," said Jeff Mateer, general counsel of Liberty Institute. "These new regulations are a mere hand wave to Americans who, inspired by their deep religious commitment, oppose providing drugs that may kill an unborn baby."

Last month, in the wake of the Hobby Lobby and Wheaton College Supreme Court decisions prohibiting the Obama Administration from forcing religious employers to facilitate or provide coverage for these abortifacient drugs, the administration announced that it would issue new regulations that would protect religious employers' religious freedom. Those new regulations, issued today, keep the same fundamental system in place to which so many employers have objected.

Under the "religious accommodation," religious organizations could submit a form that would trigger a requirement that the organization's insurance provider cover the objectionable drugs. Many faith-based organizations objected that forcing their insurance providers to cover drugs like Plan B and Ella was no less morally objectionable than including the drugs directly in the organizations' health insurance policies.

Liberty Institute is a nonprofit legal group dedicated to defending and restoring religious liberty across America — in our schools, for our churches, in the military and throughout the public arena. Liberty's vision is to reestablish religious liberty in accordance with the principles of our nation's Founders. For information, visit www.LibertyInstitute.org.

Logo - http://photos.prnewswire.com/prnh/20120523/DC12743LOGO-b


'/>"/>
SOURCE Liberty Institute
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Liberty Design Secures GSA Award, to Supply Federal Agencies
2. New England Laser Options Adds On Professional Hair Removal with the Astanza Liberty IPL System
3. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
4. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
5. The American Council for Patient Liberty on medical marijuana vending machines
6. Liberty Dialysis Celebrates Milestone 1,000th Patient in Peritoneal Dialysis Program
7. Incentivated Helps Scottish Government Service Consumers by SMS
8. Government Affairs & Public Policy Groups Playing Critical Role in Patient Engagement, Reports Best Practices, LLC
9. State Governments May Spend $55 Billion on Hepatitis C Medications
10. Government Testing Error Forces Delay in Planned Launch of New MSA Air Masks
11. AMRI Awarded Development and Manufacture Contract from the UK Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... 14, 2017  Johnson & Weaver, LLP announces that a ... Zimmer Biomet Holdings, Inc. (NYSE: ZBH )  securities ... 2016 (the "Class Period"). Zimmer Biomet provides musculoskeletal ... reconstructive products, such as knee and hip reconstructive products. ... According to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... 2017 , ... "On Tour is a music themed slideshow production package which ... Austin - CEO of Pixel Film Studios. , On Tour’s new slide presets ... animation of their slideshows. Place each slide on top of another slide or piece ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
(Date:1/13/2017)... ... January 13, 2017 , ... An inventor from Virginia Beach, Va., is always ... order to diversify my outfits, so he decided to design something that enhances the ... the appearance of a belt to allow for quick, easy changing of its look. ...
(Date:1/13/2017)... , ... January 13, 2017 , ... MyGenetx, a molecular ... Communications, and Sales Administration Specialist, Mary Taylor Smith, RD, LD, will serve on the ... serving one year as a board member and one year as Vice President. She ...
Breaking Medicine News(10 mins):